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Correspondence 
To the Editor 
Our recently published study using electronic health records from primary care setting in 
the UK examined low-density lipoprotein cholesterol (LDL-C) reduction among patients 
initiating statins.1 We are grateful to Dr Taher Modarressi, Dr Dieter Lütjohann, 
Professor Oliver Weingärtner, Dr Tülin Muggleton and Dr Ellis Muggleton for their 
comments. 
With regards to the points raised: 
Suboptimal cholesterol response to initiation of statins and future risk of cardiovascular 
disease – Dr Taher Modarressi 
While biomarkers are useful to establish associations with various disease conditions 
including cardiovascular disease (CVD), often these biomarkers are not routinely offered 
or measured in primary care settings within the UK, and hence are not available in 
electronic health records. Lipoprotein(a) (Lp(a)), a large lipoprotein particle produced in 
the liver, is not routinely measured in patients in UK general practice. There is, however, 
evidence indicating Lp(a) might be a useful biomarker that has a causal link to 
atherosclerosis and associated with cholesterol-lowering response and CVD risk.2 More 
research is required to evaluate the adoption and clinical utility of1 Lp(a) in routine 
primary care settings. 
High cholesterol absorption and response to statin therapy – Dr Dieter Lütjohann and 
Professor Oliver Weingärtner 
As rightly indicated and observed in ‘4S’3 and ‘HIJ-PROPER’4 trials, there is a need for 
individualised cholesterol-lowering therapies, and cholesterol absorption has a particular 
role in indicating specific types of cholesterol-lowering therapies. In addition to biological 
markers for cholesterol absorption, common genetic variants identified in by the SEARCH 
consortium,5 such as SLC01B1, also indicate that genetics may have a role to play in 
simvastatin-induced myopathy. These complex factors rightly indicate the need for 
personalised therapies. Critically, improving monitoring of LDL-C response and 
consideration of ongoing titration or alternative medications for patients initiated on 
statin therapy will help ensure appropriate management can be implemented to achieve 
the recommended reductions in LDL-C.6 7 
LDL-C consists of different subclasses, more precise diagnostics are required – Dr Tülin 
Muggleton and Dr Ellis Muggleton 
We acknowledge the importance of all-cause mortality; however, the outcomes of our 
study were only focused on major adverse cardiac outcomes (MACE), including CVD 
mortality. There is strong evidence to show that reduction in lipids will reduce both non-
fatal and fatal CVD from randomised trials.8 However, evidence on the effects of statins 
on non-CVD mortality is uncertain because this is extremely complex.9 The current 
study was not designed and powered to evaluate this association between statin 
response and non-CVD mortality. 
Although low-density lipoprotien (LDL) in the form of small dense LDL (sdLDL) is 
associated with elevated levels of apolipoprotein B and is more likely to lead to the 
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development of atherosclerosis,10 11 sdLDL is also not routinely measured in UK 
primary care. Per cent change in LDL-C, therefore, remains the most widely measured 
surrogate measure of statin response. 
Furthermore, primary care electronic health records have no data on medication 
adherence. Non-adherence was offered as a possible explanation for suboptimal 
response in our study. Poor adherence to statins and other medications administered for 
chronic conditions have been reported in a number of studies.12 As a research team, we 
are actively investigating the side effect profile and other factors such as polypharmacy, 
comorbidities and medication interactions that might potentially be related to suboptimal 
response. 
Finally, we agree that considering the reference group as the suboptimal responders 
mean that optimal responders have reduced risk of cardiovascular disease. In fact, this 
interpretation is supported in the supplemental analysis in our original paper (online 
supplementary appendix 5)1 that a reduction of 1 mmol/L results in a 6% reduction in 
the risk of MACE outcomes. However, it remains factual and statistically correct as well 
that those who do not respond are at increased risk of CVD when compared with those 
who do not achieve recommended reductions in LDL-C. 
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